(NASDAQ: GLSI) Greenwich Lifesciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 104.9%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 3,355.66%.
Greenwich Lifesciences's earnings in 2026 is -$19,475,704.On average, 4 Wall Street analysts forecast GLSI's earnings for 2026 to be -$19,219,017, with the lowest GLSI earnings forecast at -$20,094,623, and the highest GLSI earnings forecast at -$18,038,610.
In 2027, GLSI is forecast to generate -$20,773,496 in earnings, with the lowest earnings forecast at -$19,958,849 and the highest earnings forecast at -$21,384,481.